Trials / Completed
CompletedNCT04826185
A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Imbria Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMB-1018972 | Modified release (MR) oral tablet |
| DRUG | Placebo | Matching oral tablet |
Timeline
- Start date
- 2021-06-14
- Primary completion
- 2023-09-18
- Completion
- 2023-09-18
- First posted
- 2021-04-01
- Last updated
- 2024-04-23
Locations
14 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04826185. Inclusion in this directory is not an endorsement.